FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFIC	CIAL OWI	NERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Gollob Jared (Last) (First) (Middle) C/O KYMERA THERAPEUTICS, INC.						2. Issuer Name and Ticker or Trading Symbol Kymera Therapeutics, Inc. [KYMR] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2022								5. Ri (Che	Director Officer below)	able)	-	10% Ow Other (s below)	/ner	
200 ARSENAL YARDS BLVD., SUITE 230					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
WATERTOWN MA 02472												7	X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(S	itate)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		Transaction Disposed Of (D) Code (Instr. 5)		es Acquired (A) or Of (D) (Instr. 3, 4 and			5. Amou Securitie Benefici Owned F Reporter	s Forn ally (D) o ollowing (I) (Ir		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
										ode V		Amount	mount (A) or (D)		Price	Transact	Transaction(s) (Instr. 3 and 4)			(III3ti. 4)
Common Stock 03/01/					/2022		I	A		12,600 ⁽¹⁾ A		\$0.00	0 37,257			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution Date, or Exercise (Month/Day/Year) if any			ansaction of ode (Instr. Derivative		vative urities uired or oosed O) (Instr.	6. Date Exercisable and Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exerc	cisable		kpiration ate	Title	OI N Of	umber					
Stock Option (Right to Buy)	\$38.53	03/01/2022			A			75,800	((2)	02	2/29/2032	Commo Stock	n 7	5,800	\$0.00	75,800)	D	

Explanation of Responses:

- 1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date.
- 2. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date.

Remarks:

/s/ Bruce Jacobs, as Attorney-

03/03/2022

in-Fact ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.